Liver Diseases  >>  tivantinib (ARQ 197)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
NCT00988741: Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy

Checkmark ESMO 2016
Oct 2016 - Oct 2016: ESMO 2016
Checkmark Tumor and plasma biomarker analysis from ARQ 197-215 trial for 2L HCC at ASCO GI 2016
Jan 2016 - Jan 2016: Tumor and plasma biomarker analysis from ARQ 197-215 trial for 2L HCC at ASCO GI 2016
Checkmark For hepatocellular carcinoma
More
Completed
2
107
US, Canada, Europe
ARQ 197, Tivantinib, Placebo
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
Unresectable Hepatocellular Carcinoma
10/11
03/12

Download Options